00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
04:56 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Ultragenyx reports interim Phase I/II data for DTX301 in OTC deficiency

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported interim data from three evaluable patients in the first cohort of a Phase I/II trial evaluating a single peripheral IV infusion of 2x10 12 GC/kg DTX301 to treat ornithine transcarbamylase...
18:13 , Dec 8, 2017 |  BioCentury  |  Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
23:30 , Oct 2, 2017 |  BC Extra  |  Company News

RegenxBio won't match Ultragenyx's Dimension offer

Gene therapy company Dimension Therapeutics Inc. (NASDAQ:DMTX) said it regards a takeout offer from rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) as superior to its existing merger agreement with RegenxBio Inc. (NASDAQ:RGNX), and that RegenxBio...
20:10 , Sep 22, 2017 |  BC Week In Review  |  Company News

Ultragenyx counters RegenxBio with bid for Dimension

On Sept. 18, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. In August, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire...
21:30 , Sep 18, 2017 |  BC Extra  |  Company News

Ultragenyx counters RegenxBio with bid for Dimension

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. Last month, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire Dimension in a...
18:02 , Sep 1, 2017 |  BC Week In Review  |  Company News

RegenxBio acquiring gene therapy play Dimension

RegenxBio Inc. (NASDAQ:RGNX) will acquire Dimension Therapeutics Inc. (NASDAQ:DMTX) in a stock deal. For each share held, Dimension shareholders will receive 0.1573 RegenxBio shares, which the companies say implies a value of $3.41 per Dimension...
20:28 , Aug 25, 2017 |  BC Extra  |  Company News

RegenxBio acquiring gene therapy play Dimension

RegenxBio Inc. (NASDAQ:RGNX) will acquire Dimension Therapeutics Inc. (NASDAQ:DMTX) in a stock deal. For each share held, Dimension shareholders will receive 0.1573 RegenxBio shares, which the companies say implies a value of $3.41 per Dimension...
07:00 , May 25, 2015 |  BioCentury  |  Emerging Company Profile

Dimension's intentions

With an industry veteran at the helm and its lead program partnered and paid for, Dimension Therapeutics Inc. aims to develop safer and more potent gene therapies by packaging as many gene copies into capsids...